Fakhraee 2007.

Methods	Single centre randomised controlled trial in Tehran, Iran. Study period: June 2003 to June 2004
Participants	36 preterm infants PMA < 34 weeks, aged ≤ 14 days, platelet count > 100,000/μL, serum creatinine ≤ 1.6 mg/dL, absence of clinical manifestations of abnormal clotting function, absence of grades III‐IV IVH. Colour Doppler ECHO evidence of significant PDA Ibuprofen: 18 infants, mean (SD) PMA 31.5 (1.4) weeks; BW 1658 (387) grams Indomethacin: 18 infants, mean (SD) PMA 30.9 (2.0) weeks; BW 1522 (358) grams Study period: June 2003 to June 2004
Interventions	Ibuprofen: orally as a suspension at a first dose of 10 mg/kg, followed at an interval of 24 hours by 2 doses of 5 mg/kg Indomethacin: orally 3 times at 0.2 mg/kg/dose at intervals of 24 hours
Outcomes	Ductal closure, need for re‐treatment, reopening of the duct, mortality during the first 30 days of life, maximum serum BUN and creatinine levels, NEC, IVH (grades III‐IV), oliguria
Notes	No information on funding provided
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	No description provided
Allocation concealment (selection bias)	Unclear risk	No description provided. "The enrolled patients randomly received either oral ibuprofen or oral indomethacin"
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	No information provided
Blinding of outcome assessment (detection bias) All outcomes	Low risk	ECHOs were performed by a paediatric cardiologist, who was blinded to the infants' treatment
Incomplete outcome data (attrition bias) All outcomes	Low risk	Outcomes were reported for all enrolled infants
Selective reporting (reporting bias)	Unclear risk	The protocol was not available to us, so we could not judge if there were any deviations
Other bias	Low risk	Appeared free of other bias